Unigene Laboratories, Inc. (OTC BB: UGNE), a biopharmaceutical company, engages in the research, production and delivery of small proteins that have shown or may potentially demonstrate medical benefits. In addition to the company’s patented manufacturing technology designed to produce many peptides cost-effectively, Unigene has patented oral and nasal delivery technologies that have demonstrated the ability to deliver medically useful amounts of various peptides into the bloodstream. For further information, visit the Company’s web site at www.unigene.com.
- 18 years ago
QualityStocks
Unigene Laboratories, Inc. (OTC BB: UGNE)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…